Aeolus Pharmaceuticals – Separation Agreement and General Release (December 7th, 2006)
Special Payments: My termination of employment will be deemed effective as of the close of business on November 30, 2006 (the "Termination"). Although the Company has no policy or procedure for providing severance benefits, the Company will pay me a severance payment (the "Severance Payment") in the form of a continuation of my base salary in effect as of immediately prior to the Termination for the period commencing on December 1, 2006 and ending at the close of business on February 28, 2007 (the "Transition Period"). The Severance Payment will be paid to me by check as a lump sum immediately following the Effective Time (as defined in Section (f) below). The Company will withhold taxes and report this Severance Payment to tax
Aeolus Pharmaceuticals – Right of First Offer Agreement (June 6th, 2006)
Aeolus Pharmaceuticals – Aeolus Pharmaceuticals, Inc. Warrant to Purchase [*] Shares of Common Stock (June 6th, 2006)
This Warrant is one of a number of Warrants (collectively, the "Warrants") being issued pursuant that certain Subscription Agreement dated as of June 5, 2006, by and among the Company and the Investors party thereto (the "Subscription Agreement").
Aeolus Pharmaceuticals – June 5, 2006 (June 6th, 2006)
This letter agreement will confirm our agreement that pursuant to the purchase of shares of common stock of Aeolus Pharmaceuticals, Inc., a Delaware corporation (the "Company"), by Efficacy Biotech Master Fund Ltd. ("Investor"), Investor will be entitled to the following rights:
Aeolus Pharmaceuticals – Conversion Agreement (June 6th, 2006)
THIS CONVERSION AGREEMENT (this "Agreement") is made and entered into as of June 5, 2006, by and among AEOLUS PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and the parties who are signatories hereto.
Aeolus Pharmaceuticals – CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES a CONVERTIBLE PREFERRED STOCK OF AEOLUS PHARMACEUTICALS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) (November 23rd, 2005)
Aeolus Pharmaceuticals, Inc. (the "Corporation"), a corporation organized and existing under the laws of the State of Delaware, hereby certifies that, pursuant to authority conferred on its Board of Directors (the "Board") by the Certificate of Incorporation of the Corporation, as amended (the "Certificate of Incorporation"), the following resolution was adopted by the Board by a unanimous written consent of the Board, dated as of October 25, 2005, in lieu of a meeting in accordance with Section 141(f) of the Delaware General Corporation Law, which resolution remains in full force and effect on the date hereof:
Aeolus Pharmaceuticals – Registration Rights Agreement (November 23rd, 2005)
This Registration Rights Agreement (the "Agreement") is made and entered into as of this 21st day of November, 2005 by and among Aeolus Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and the "Investors" named in that certain Purchase Agreement dated as of the date hereof by and among the Company and the Investors (including any Investors that may hereafter become a party to the Purchase Agreement in accordance with its terms) (the "Purchase Agreement"). Capitalized terms used but not otherwise defined in this Agreement shall have the meanings set forth in the Purchase Agreement.
Aeolus Pharmaceuticals – McManus & Company, Inc. 23811 Inverness Place Laguna Niguel, California 92677 (June 21st, 2005)
This will confirm the terms of our mutual understanding and agreement (Agreement) in connection with the efforts of McManus & Company, Inc. (M&C) to provide consulting services to Aeolus Pharmaceuticals, Inc. or its affiliates, sister companies or principals (collectively the Company or Aeolus) as follows:
Aeolus Pharmaceuticals – Separation Agreement and General Release (June 21st, 2005)
Aeolus Pharmaceuticals, Inc. and I, Richard Reichow, have entered into this agreement (Release) to settle all issues between us in connection with my termination of employment. Except to the extent governed by federal law, this Release shall be governed by the statutes and common law of North Carolina, excluding any that mandate the use of another jurisdictions laws.
Aeolus Pharmaceuticals – Consulting Agreement (June 21st, 2005)
This CONSULTING AGREEMENT is entered into by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 79 T. W. Alexander Drive, 4401 Research Commons, Suite 200, P.O. Box 14287, Research Triangle Park, NC 27709 (Aeolus), and John L. McManus, having a place of business at 23811 Inverness Place, Laguna Niguel, CA 92677 (Consultant).
Aeolus Pharmaceuticals – Aeolus Pharmaceuticals, Inc. Announces Optimistic AEOL 10150 Phase 1 Clinical Trial Interim Results in Patients With Lou Gehrigs Disease (March 29th, 2005)
First three single doses of 3, 12 and 30 mg well tolerated with no serious adverse events; 30 mg dose is 3X to 10X higher than presumed efficacious dose in humans additional dosing evaluation on-going.
Aeolus Pharmaceuticals – Consulting Agreement (February 23rd, 2005)
This CONSULTING AGREEMENT is entered into by and between Aeolus Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 79 T. W. Alexander Drive, 4401 Research Commons, Suite 200, P.O. Box 14287, Research Triangle Park, NC 27709 (Aeolus), and Elaine Alexander, M.D., Ph.D., having a place of business at 4945 Canterbury Dr., San Diego, CA 92116 (Consultant).
Aeolus Pharmaceuticals – [ Aeolus Pharmaceuticals, Inc. Letterhead ] (January 6th, 2005)
This letter confirms our previous conversations regarding the employment opportunity available to you with Aeolus Pharmaceuticals, Inc. (the Company) and sets forth the terms and conditions of that employment.